Empagliflozin（Jardiance）市場規模、佔有率和成長分析：按適應症、劑量、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Empagliflozin（Jardiance ）市值為 186.2 億美元，預計到 2033 年將從 2025 年的 207.4 億美元成長至 492 億美元，預測期（2026-2033 年）的複合年成長率為 11.4%。

Empagliflozin（商品名： Jardiance ）是SGLT2抑制劑市場的領導藥物。由於該藥能有效降低第2型糖尿病患者心血管死亡風險，因此市場成長顯著。恩格列淨改善血糖控制並最大限度降低心臟衰竭風險的能力影響了處方趨勢，促使保險公司優先考慮該藥物而非傳統療法。這種轉變使Empagliflozin從一種小眾產品發展成為一種價值數十億美元的藥物，並成為區域治療指南中不可或缺的一部分。值得關注的趨勢包括恩格列淨在心臟衰竭和慢性腎臟病的應用不斷擴大。強力的臨床證據支持了這一趨勢，增強了醫生的信心，並促進了該藥物被納入處方藥清單和醫療保險報銷範圍。因此，隨著新興市場（尤其是代謝性疾病市場）對該藥物的需求不斷成長，恩格列淨預計將維持兩位數的持續成長。

全球Empagliflozin（Jardiance）市場成長要素

隨著全球第2型糖尿病盛行率的不斷上升，對有效降血糖療法的需求持續成長，Empagliflozin因其已證實的心血管獲益而成為首選治療方案。醫療專業人員越來越重視那些不僅能控制血糖值，還能降​​低相關健康風險的療法，這促使該藥物在基層醫療機構和專科醫療機構中的應用日益廣泛。此外，患者對糖尿病長期併發症的認知不斷提高，也促使更多患者尋求能帶來更好健康結果的療法。這種日益成長的支持使得Empagliflozin更有可能被納入全球藥品目錄，從而進一步擴大其市場佔有率。

全球Empagliflozin（Jardiance）市場的限制因素

由於Empagliflozin（Jardiance）的價格相對於其他抗糖尿病非專利藥較高，其市場面臨嚴峻挑戰，這引發了人們對預算緊張的醫療體系能否負擔得起該藥的擔憂。在許多醫療預算有限的地區，保險公司往往優先考慮更經濟的替代藥物，這阻礙了Empagliflozin的市場滲透。此外，患者高昂的自付費用會影響治療順從性，尤其是在缺乏全面健保覆蓋的情況下。儘管恩格列淨具有臨床療效，但這種經濟負擔限制了其應用，阻礙了市場成長。此外，價格談判的延遲也可能進一步影響該藥在各地區的供應。

Empagliflozin（Jardiance）全球市場趨勢

全球Empagliflozin（Jardiance ）市場正呈現出顯著的趨勢，其適應症正從傳統的糖尿病治療擴展到其他領域。製藥公司日益重視臨床試驗，以凸顯Empagliflozin在心血管疾病、腎臟疾病和心臟衰竭治療的療效。這種多適應症策略不僅吸引了專家的關注，也有助於將其納入健保報銷範圍，並將Empagliflozin整合到綜合慢性病管理方案中。隨著保險公司逐漸認知到單一藥物治療多種合併症的經濟和治療價值，處方模式正朝著早期應用的方向轉變，從而推動市場成長，並在全球主要醫療保健市場創造新的機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

Empagliflozin（Jardiance）全球市場規模：依適應症分類

• 2型糖尿病
• 心臟衰竭
• 慢性腎臟病

Empagliflozin（Jardiance）全球市場規模：以劑量強度分類

• 10 mg
• 25 mg

Empagliflozin（Jardiance）全球市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

Empagliflozin（Jardiance）全球市場規模：依最終用戶分類

• 醫院
• 診所
• 居家照護

Empagliflozin（Jardiance）全球市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Limited
• Sun Pharmaceutical Industries Limited
• Zydus Lifesciences Limited
• Cipla Limited
• Aurobindo Pharma Limited
• Alkem Laboratories Limited
• Macleods Pharmaceuticals Limited
• Glenmark Pharmaceuticals Limited
• Intas Pharmaceuticals Ltd.
• MSN Laboratories Pvt. Ltd.
• Hetero Labs Limited
• Biocon Limited
• Sandoz Group AG
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• STADA Arzneimittel AG

結論與建議

Global Empagliflozin (Jardiance) Market size was valued at USD 18.62 Billion in 2024 and is poised to grow from USD 20.74 Billion in 2025 to USD 49.2 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).

Empagliflozin, known as Jardiance, stands at the forefront of the SGLT2-inhibitor market, which has experienced substantial growth due to the drug's efficacy in reducing cardiovascular mortality in individuals with type-2 diabetes. Its ability to enhance glucose control and minimize heart-failure risk has influenced prescribing trends, prompting insurers to prioritize it over traditional treatments. This shift has transitioned empagliflozin from a niche player to a billion-dollar entity integral to treatment guidelines across various regions. A notable trend is the broadening of its usage in heart failure and chronic kidney disease, bolstered by strong clinical evidence that enhances physician trust, formulary acceptance, and reimbursement. Consequently, sustained double-digit growth is anticipated as the drug extends its reach in emerging markets grappling with metabolic diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Empagliflozin (Jardiance) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Empagliflozin (Jardiance) Market Segments Analysis

Global empagliflozin (jardiance) market is segmented by indication, dosage strength, distribution channel, end user and region. Based on indication, the market is segmented into type 2 diabetes, heart failure and chronic kidney disease. Based on dosage strength, the market is segmented into 10 mg and 25 mg. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, clinics and home care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Empagliflozin (Jardiance) Market

The growing prevalence of type 2 diabetes worldwide leads to an ongoing demand for effective glucose-lowering therapies, establishing empagliflozin as a favored choice due to its demonstrated cardiovascular advantages. Healthcare professionals increasingly emphasize treatments that not only manage blood sugar levels but also mitigate associated health risks, resulting in a wider adoption of this medication in both primary and specialty care settings. Additionally, heightened patient awareness regarding the long-term complications of diabetes encourages individuals to pursue treatments that promise better health outcomes. This increased endorsement facilitates the inclusion of empagliflozin in formulary lists globally, further boosting its market presence.

Restraints in the Global Empagliflozin (Jardiance) Market

The Empagliflozin (Jardiance) market faces significant challenges due to its relatively high pricing when compared to generic antidiabetic medications, which raises affordability concerns for budget-conscious healthcare systems. In many areas with constrained healthcare funding, payers tend to favor more economical alternatives, thereby hindering Empagliflozin's market penetration. Additionally, high out-of-pocket costs for patients can negatively impact treatment adherence, particularly in situations where insurance does not offer comprehensive coverage. This financial burden limits broader adoption of the drug and stifles market growth, despite its clinical benefits. Additionally, discussions around pricing reductions may experience delays, further impacting the drug's availability in various regions.

Market Trends of the Global Empagliflozin (Jardiance) Market

The global empagliflozin (Jardiance) market is experiencing a notable trend toward expanding its therapeutic indications beyond traditional diabetes treatment. Pharmaceutical companies are increasingly focusing on clinical trials that highlight empagliflozin's efficacy in managing cardiovascular, renal, and heart failure conditions. This multi-indication approach not only attracts specialty physicians but also enhances formulary placements and integrates empagliflozin into comprehensive chronic disease management programs. As insurers begin to recognize the economic and therapeutic value of a single medication that addresses multiple comorbidities, there is a shift in prescribing patterns toward earlier adoption, thus driving market growth and creating new opportunities across key healthcare markets globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Empagliflozin (Jardiance) Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 2 Diabetes
• Heart Failure
• Chronic Kidney Disease

Global Empagliflozin (Jardiance) Market Size by Dosage Strength & CAGR (2026-2033)

• Market Overview
• 10 mg
• 25 mg

Global Empagliflozin (Jardiance) Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Empagliflozin (Jardiance) Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Home Care

Global Empagliflozin (Jardiance) Market Size & CAGR (2026-2033)

• North America (Indication, Dosage Strength, Distribution Channel, End User)
  • US
  • Canada
• Europe (Indication, Dosage Strength, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Dosage Strength, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Dosage Strength, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Dosage Strength, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Labs Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STADA Arzneimittel AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations